DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan

Inclusion Criteria: * Healthy males. * Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.. * Age 18 to 55 (inclusive) years of age at the time of signing informed consent. * Body mass index (BMI) of 18.0 to 30.0 kg/m2 as measured at screening. * Body weight not less than 50 kg. * Non-smokers (defined as has not used nicotine-containing products including e-cigarette for at least 3 months prior to the first dose as confirmed by cotinine test). * Must be willing and able to communicate and participate in the whole study. * Normal blood pressure (BP): Systolic BP (SBP) between 90 and 140 mmHg (inclusive), diastolic BP (DBP) between 45 and 90 mmHg (inclusive), measured after 10 min rest in supine position at screening and first admission (Day -1). * A resting heart rate (HR) between 45 and 90 bpm (inclusive), measured after 10 min rest in supine position at screening and first admission (Day -1). * ECG recording without clinically significant abnormality, including Fridericia's corrected interval between Q and T waves (QTcF) measure of ≤450 msec at screening and first admission (Day -1). * Participants must be able to swallow multiple capsules. Exclusion Criteria: * Have participated in an investigational trial involving administration of any investigational compound within 90 days prior to the study dosing or 5-times the half-life of the drug tested in the previous clinical trial, whichever …